Research Article

Ifosfamide, Carboplatin, and Etoposide (ICE) in Combination with Regional Hyperthermia as Salvage Therapy in Patients with Locally Advanced Nonmetastatic and Metastatic Soft-Tissue Sarcoma

Table 1

Patients’ characteristics and pretreatment. values, representing differences between patients with locally advanced disease and patients with metastatic disease, were assessed by Fisher’s exact test for sex, progression vs. relapse, grading, and pretreatment procedures, by the chi-square test for anatomic site and histopathologic subtype, and by the unpaired t-test for age.

Locally advanced diseaseMetastatic disease
(LA-STS, n = 54) No. (%)(M-STS, n = 56) No. (%)

Age0.23
 Median (range)56 (18–74) years51 (21–77) years
 <51 years16 (29.6)27 (48.2)
 >50 years38 (70.4)29 (51.8)

Sex0.26
 Male31 (57.4)26 (46.4)
 Female23 (42.6)30 (53.6)

Progression vs. relapse0.01
 Progression of pre-existing lesion(s)22 (40.7)37 (66.1)
 Relapse after disease-free interval32 (59.3)19 (33.9)
 Median (range) duration of the disease-free interval27 (9–171) months14 (2–115) months

Anatomic site0.16
 Head and neck2 (3.7)1 (1.8)
 Extremities and trunk wall23 (42.6)30 (53.6)
  Extremities18 (33.3)17 (30.4)
  Trunk wall5 (9.3)13 (23.2)
 Trunk29 (53.7)25 (44.6)
  Abdomen10 (18.5)15 (26.8)
  Retroperitoneum13 (24.1)6 (10.7)
  Pelvis6 (11.1)4 (7.1)

Site of metastasis (multiple sites possible)
 Lung35 (62.5)
 Liver13 (23.2)
 Nodal8 (14.3)
 Soft tissue7 (12.5)
 Osseous3 (5.4)
 Other8 (14.3)

Histopathologic subtype0.051
 Liposarcoma20 (37.0)6 (10.7)
  Myxoid2 (3.7)0 (0.0)
  Dedifferentiated18 (33.3)6 (10.7)
 Leiomyosarcoma8 (14.8)16 (28.6)
 Rhabdomyosarcoma2 (3.7)4 (7.1)
 Undifferentiated pleomorphic sarcoma (UPS)11 (20.4)14 (25.0)
 Synovial sarcoma1 (1.9)3 (5.4)
 MPNST5 (9.2)4 (7.1)
 Other7 (13.0)9 (16.1)

FNCLCC grading0.32
 Grade 222 (40.7)17 (30.4)
 Grade 332 (59.3)39 (69.6)

Pretreatment
 1 regimen46 (85.2)40 (71.4)0.11
 >1 regimen8 (14.8)16 (28.6)
 Anthracycline-containing54 (100.0)56 (100.0)
 Ifosfamide-containing52 (96.3)55 (98.2)
 Surgery48 (88.9)45 (80.4)0.29
 Radiotherapy31 (57.4)18 (32.1)0.02

MPNST: malignant peripheral nerve sheath tumor.